Pi Health has announced a partnership to deliver completely outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of trial processes.
The companies have formalised their collaboration through a master clinical services outsourcing agreement and have commenced activities for a worldwide Phase II clinical trial in oncology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Pi Health will oversee all facets of the clinical trial via its technology-powered service model.
This encompasses selection and activation of trial sites, enrolment of subjects, study execution, monitoring in real time, and regulatory submissions.
The collaboration focuses on Pi Health’s front-end interoperable capture system (FICS) software platform, which is integrated with a global network of trial sites.
FICS is a comprehensive clinical trial platform equipped with AI capabilities, designed to link sponsors and sites to expedite the trial process.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt can also accelerate study conduct by 50% while ensuring audit-ready data quality.
Pi Health’s operational and technology workflows facilitate regulatory-grade capturing of data throughout the trial lifecycle, allowing for real-time preparedness aimed at regulatory reviews and removing the need for manual reconciliation.
Pi Health CEO and co-founder Geoffrey Kim said: “By applying Pi Health’s technology and international reach to GSK’s global scale and expertise, we believe we can accelerate the development of vital treatments for patients in need of new therapies by making clinical trials faster and more efficient.”
GSK senior vice-president and oncology clinical development head Zeshaan Rasheed said: “Pi Health’s integrated approach to clinical trial management, and its team’s strong background in drug development and regulation, made them a natural choice.
“By removing inefficiencies that can slow progress in clinical trials, Pi Health is well positioned to help us focus on our main priority: getting innovative medicines to people with cancer as quickly and as safely as possible.”
